Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IS Pharma
With Parkinson's affecting about six million people worldwide – with some estimates putting it as high as 10 million – and the condition becoming increasingly burdensome on health systems around the globe, "we don't have to do a lot of convincing" the disease is worthwhile to invest in and pursue for new treatments, said Todd Sherer, CEO of the Michael J. Fox Foundation (MJFF).
Some people reckon that what others say of us is none of our business. It's a useful maxim for retaining sanity in the Twitter and Google age, but perhaps there are times when a bit of constructive criticism is good for the soul. We all know that the public perception of the pharma industry isn't great, but the opinions of an Ivy League economics professor laid out in a recent JAMA Forum commentary may sting. Paraphrasing, it seems Professor Uwe Reinhardt thinks you're a bit spoilt: fragile little birds shielded by government from the harsh realities of the free market, and enjoying monopoly positions. He's got a point.
Everybody's wondering, when will the biotech bubble burst? Whilst there have been IPOs cancelled citing "market conditions", news of many more primary and secondary offerings continues to appear in our in boxes. Logic dictates that the bubble will burst eventually and indeed in the last year we've already had two warning pops caused by drug pricing concerns, but the NASDAQ Biotech Index has continued its relentless climb. Even so, fresh evidence is appearing that the bubble is about to die, starting with this latest earnings season
As late as last year, some pundits were predicting that the emerging economies of the BRIC countries – Brazil, Russia, India and China – would be the salvation of the multinational pharmaceutical companies that were facing growing generic competition and lacklustre pipelines in their domestic markets.